Endoluminal Angioplasty of the Popliteal Artery. Review of 54 Consecutive Patients

Raouf, A. Abdul; Rouleau, Y; Clément, A; Roux, Philippe Le; Genay, P.; Ricco, Jean‐Baptiste

doi:10.1016/j.ejvs.2005.06.014

Cited by 13 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a new item, the TASC II type B femoropopliteal lesion category now includes single popliteal stenoses. In support of this expansion, TASC II Working Group member White 11 cited a retrospective review by Abdul Raouf et al 44 of 54 PTA procedures (adjunctive stent placement in 6 cases) for popliteal lesions (12-mm mean length) in 50 patients, all with patent SFAs. For the entire cohort, primary patency was 57.4% at 1 and 2 years, while assisted primary patency was 86.3% at 1 year and 79.1% at 2 years.…”

Section: Evidence Supporting the Tasc II Femoropopliteal Reclassificationmentioning

confidence: 99%

TASC II and the Endovascular Management of Infrainguinal Disease

Lyden

Smouse

2009

Journal of Endovascular Therapy

View full text Add to dashboard Cite

The stratifications of aortoiliac, femoropopliteal, and infrapopliteal lesions included in the original comprehensive report of the TransAtlantic Inter-Society Consensus (TASC I) have been commonly used to formally characterize clinical trial populations and to channel investigative discussion among clinicians, while the associated treatment recommendations have become outdated as compared to current clinical practice. The TASC II report is an abbreviated update focusing on key areas of diagnosis and management of peripheral artery disease, with revised stratifications of aortoiliac and femoropopliteal lesions but not infrapopliteal disease. The consensus document keeps new lesion stratifications linked to the same structure of recommendations for initial treatment: endovascular for type A, endovascular (with qualifications) for type B, open surgical (with qualifications) for type C, and open surgical for type D. In general, each TASC II lesion category includes more severe disease than in TASC I, but the TASC II report does not recommend specific endovascular modalities for infrainguinal occlusive disease. We discuss how the new TASC II femoropopliteal lesion categories reflect current research outcomes and clinical practice, including summarized results from some more recent studies that have demonstrated the ability to treat by endovascular means increasingly complex femoropopliteal lesions that would actually be classifiable as type C. Noting that TASC II does not include a separate stratification of infrapopliteal lesions, as did TASC I, we review evidence of recent endovascular treatment of infrapopliteal lesions and contend that TASC classifications in this anatomical area should be upgraded.

show abstract

Section: Evidence Supporting the Tasc II Femoropopliteal Reclassificationmentioning

confidence: 99%